Respuesta :
To determine if ALLN-177, an oral oxalate-specific enzyme treatment, can lower individuals with secondary hyperoxaluria's excretion of oxalate in their urine (UOx).
What is the result of this study?
Five participants had enteric hyperoxaluria and eleven had idiopathic hyperoxaluria in the research. ALLN-177 was accepted well. While receiving ALLN-177 medication, the overall mean (SD) UOx dropped from 77.7 (55.9) mg/24 h at baseline to 63.7 (40.1) mg/24 h, with a mean decrease of 14 mg/24 h (95% CI - 23.71, - 4.13). In the entire population, the ratio of urine calcium oxalate supersaturation dropped from a mean of 11.3 (5.7) to 8.8 (3.8) (- 2.8; 95% CI - 4.9, - 0.79). None of the other urine indicators contributed to this difference; only the reduction of oxalate did. Oxalate, calcium, and hydration intake on a daily basis as determined by frequent diet recall did not vary between research periods.
What is the conclusion of this study?
ALLN-177 was well tolerated and decreased 24-h UOx excretion. The outcomes of this pilot study justified additional research on ALLN-177 in individuals with secondary hyperoxaluria.
Learn more about excretion: https://brainly.com/question/9316155
#SPJ4
